Search Results | Blood | American Society of Hematology

1-20 of 112

2 3 4 5

Sort by

Sort Order Select

Journal Articles

Predictors and Outcomes of Immune Effector Cell Associated Neurotoxicity Syndrome in Patients Receiving Chimeric Antigen Receptor T-Cell Therapy for Aggressive B-Cell Non-Hodgkin Lymphoma

Vivek Patel, Shakthi Bhaskar, Stephen J. Schuster, Loretta J. Nastoupil, Miguel-Angel Perales, Roni Shouval, Joseph P. McGuirk, Richard T. Maziarz, Andy Chen, Veronika Bachanova, David L. Porter, Michael R. Bishop, Peter A. Riedell, Olalekan O. Oluwole

Blood (2022) 140 (Supplement 1): 366–368.

DOI: https://doi.org/10.1182/blood-2022-165556

Published: 2022

Journal Articles

JAK1 Inhibition during CAR T-Cell Treatment Does Not Affect CAR T-Cell Proliferation, Persistence, or Function

Michael Pratta, Lea Burke, John F. DiPersio, Richard T. Maziarz, Patricia Feldman, Teresa Brodeur, Cynthia Timmers, Olga Ivanova, April Barbour, Rodica Morariu-Zamfir, Matthew Frigault

Blood (2022) 140 (Supplement 1): 10350–10351.

DOI: https://doi.org/10.1182/blood-2022-169382

Published: 2022

Journal Articles

CTX110 Allogeneic CRISPR-Cas9-Engineered CAR T Cells in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Phase 1 Dose Escalation Carbon Study

Blood (2022) 140 (Supplement 1): 10303–10306.

DOI: https://doi.org/10.1182/blood-2022-166432

Published: 2022

Journal Articles

Cytokine Release Syndrome (CRS) Is Not Required for CAR-T Cell Efficacy in Aggressive Large B-NHL

Shakthi Bhaskar, Vivek Patel, David L. Porter, Stephen J. Schuster, Loretta J. Nastoupil, Miguel-Angel Perales, Ana Alarcon Tomas, Michael R. Bishop, Joseph P. McGuirk, Richard T. Maziarz, Andy Chen, Veronika Bachanova, Peter A. Riedell, Olalekan O. Oluwole

Blood (2022) 140 (Supplement 1): 10971–10973.

DOI: https://doi.org/10.1182/blood-2022-155886

Published: 2022

Journal Articles

Population Pharmacokinetic Model Identifies an Optimal Fludarabine Exposure for Improved Outcomes after CD19-Directed CAR T Cell Therapy for Aggressive B-NHL: Analysis from the Cell Therapy Consortium

Blood (2022) 140 (Supplement 1): 1588–1591.

DOI: https://doi.org/10.1182/blood-2022-164674

Published: 2022

Journal Articles

Breakthrough CMV Viremia Outcomes of Letermovir Prophylaxis in Haploidentical Stem Cell Transplant with Post-Transplant Cyclophosphamide

Arthur Nguyen, Joseph S Bubalo, Jennifer N. Saultz, Brandon Hayes-Lattin, Andy Chen, Rachel J. Cook, Arpita Gandhi, Jessica Leonard, Richard T. Maziarz, Yazan Migdady, Eneida R. Nemecek, Levanto Schachter

Blood (2022) 140 (Supplement 1): 12856–12858.

DOI: https://doi.org/10.1182/blood-2022-156011

Published: 2022

Journal Articles

Estimating the Lifetime Medical Cost Burden of an Allogeneic Hematopoietic Cell Transplantation Patient and the Value of Addressing the Unmet Need

Richard T. Maziarz, Steven M Devine, Louis P. Garrison, Irene Agodoa, Jack Badaracco, Matthew Gitlin, Miguel-Angel Perales

Blood (2022) 140 (Supplement 1): 10833–10834.

DOI: https://doi.org/10.1182/blood-2022-157439

Published: 2022

Journal Articles

Impact of CD19 CAR T-cell product type on outcomes in relapsed or refractory aggressive B-NHL

Blood (2022) 139 (26): 3722–3731.

DOI: https://doi.org/10.1182/blood.2021014497

Published: 2022

Includes: Supplemental data

Journal Articles

Tisagenlecleucel Vs Standard of Care As Second-Line Therapy of Primary Refractory or Relapsed Aggressive B-Cell Non-Hodgkin Lymphoma: Analysis of the Phase III Belinda Study

Blood (2021) 138 (Supplement 2): LBA-6.

DOI: https://doi.org/10.1182/blood-2021-155068

Published: 2021

Journal Articles

Bendamustine Is a Safe and Effective Regimen for Lymphodepletion before Tisagenlecleucel in Patients with Large B-Cell Lymphomas

Blood (2021) 138 (Supplement 1): 1438.

DOI: https://doi.org/10.1182/blood-2021-151766

Published: 2021

Journal Articles

A Multicenter Analysis of Outcomes, Toxicities, and Patterns of Use with Commercial Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed/Refractory Aggressive B-Cell Lymphomas

Peter A. Riedell, Jamie Brower, Loretta Nastoupil, Miguel-Angel Perales, Richard T. Maziarz, Joseph P. McGuirk, Veronika Bachanova, Wei-Ting Hwang, Stephen J. Schuster, Michael R. Bishop, David L. Porter

Blood (2021) 138 (Supplement 1): 2512.

DOI: https://doi.org/10.1182/blood-2021-151971

Published: 2021

Journal Articles

Safety and Efficacy of Two Anakinra Dose Regimens for Refractory CRS or Icans after CAR T-Cell Therapy

Blood (2021) 138 (Supplement 1): 2816.

DOI: https://doi.org/10.1182/blood-2021-147454

Published: 2021

Journal Articles

Hospitalization and Healthcare Resource Use of Omidubicel Vs Cord Blood Transplantation for Hematological Malignancies in a Global Randomized Phase III Clinical Trial

Navneet S. Majhail, Beckley Miller, Rebecca Dean, Rocio Manghani, Smitha Sivaraman, Einat Galamidi-Cohen, Richard T. Maziarz

Blood (2021) 138 (Supplement 1): 4036.

DOI: https://doi.org/10.1182/blood-2021-147480

Published: 2021

Journal Articles

Outcomes of Aggressive B Cell Lymphoma Patients with No Evidence of Measurable Disease at the Time of CD19 Chimeric Antigen Receptor T Cell Therapy: The Experience from the CAR T Cell Consortium

Kitsada Wudhikarn, Ana Alarcon Tomas, Jamie Brower, Veronika Bachanova, Richard T. Maziarz, Joseph P. McGuirk, Loretta Nastoupil, David L. Porter, Peter A. Riedell, Miguel-Angel Perales

Blood (2021) 138 (Supplement 1): 2843.

DOI: https://doi.org/10.1182/blood-2021-150012

Published: 2021

Journal Articles

Omidubicel vs standard myeloablative umbilical cord blood transplantation: results of a phase 3 randomized study

Blood (2021) 138 (16): 1429–1440.

DOI: https://doi.org/10.1182/blood.2021011719

Published: 2021

Includes: Supplemental data

Journal Articles

Early Infection after Allogeneic Transplant Increases NRM without Influencing Relapse Rate

Jennifer N Saultz, DO, Kaycee Moshofsky, BS, Andy Kaempf, MS, Guang Fan, MD PhD, Gabrielle Meyers, Rachel J. Cook, MD, Richard T. Maziarz, MD, Peggy Appel, Francisco Tria, MD, Staci Williamson, MS

Blood (2020) 136 (Supplement 1): 21.

DOI: https://doi.org/10.1182/blood-2020-142048

Published: 2020

Journal Articles

Myc Expression and Tumor-Infiltrating T Cells Are Associated with Response in Patients (Pts) with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL) Treated with Tisagenlecleucel in the Juliet Trial

Ulrich Jaeger, MD, Michael R. Bishop, MD, Gilles Salles, MDPhD, Stephen J. Schuster, MD, Richard T. Maziarz, MD, Xia Han, MS, Alexander Savchenko, MD, Nathan Roscoe, Mbt, Elena Orlando, PhD, Dawson Knoblock, PhD, Ranjan Tiwari, MSc, Lida Bubuteishvili Pacaud, MD, Paolo Corradini

Blood (2020) 136 (Supplement 1): 48–49.

DOI: https://doi.org/10.1182/blood-2020-137045

Published: 2020

Journal Articles

A Multi-Center Biologic Assignment Trial Comparing Reduced Intensity Allogeneic Hematopoietic Cell Transplantation to Hypomethylating Therapy or Best Supportive Care in Patients Aged 50-75 with Advanced Myelodysplastic Syndrome: Blood and Marrow Transplant Clinical Trials Network Study 1102

Blood (2020) 136 (Supplement 1): 19–21.

DOI: https://doi.org/10.1182/blood-2020-136828

Published: 2020

Journal Articles

Second Autologous Stem Cell Transplant As Salvage Therapy in Multiple Myeloma - the Oregon Health and Science University Experience

Derek Galligan, MD, Staci Williamson, MS, Jessie Myers, Rebecca W. Silbermann, MD, Eva Medvedova, MD, Levanto Schachter, DO,MS, Sarah J. Nagle, MD, Andy Chen, MDPhD, Richard T. Maziarz, MD

Blood (2020) 136 (Supplement 1): 8–9.

DOI: https://doi.org/10.1182/blood-2020-142770

Published: 2020

Journal Articles

A Multicenter Retrospective Analysis of Clinical Outcomes, Toxicities, and Patterns of Use in Institutions Utilizing Commercial Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed/Refractory Aggressive B-Cell Lymphomas

Peter A. Riedell, MD, Chase Walling, BS, Loretta J. Nastoupil, MD MSc, Martina Pennisi, Richard T. Maziarz, MD, Joseph P. McGuirk, DO, Olalekan O. Oluwole, MBBS, MPH, Veronika Bachanova, MD PhD, Wei-Ting Hwang, PhD, Stephen J. Schuster, MD, Miguel-Angel Perales, MD, Michael R. Bishop, MD, David L. Porter, MD

Blood (2019) 134 (Supplement_1): 1599.

DOI: https://doi.org/10.1182/blood-2019-127490

Published: 2019

2 3 4 5

NARROW

Predictors and Outcomes of Immune Effector Cell Associated Neurotoxicity Syndrome in Patients Receiving Chimeric Antigen Receptor T-Cell Therapy for Aggressive B-Cell Non-Hodgkin Lymphoma

JAK1 Inhibition during CAR T-Cell Treatment Does Not Affect CAR T-Cell Proliferation, Persistence, or Function

CTX110 Allogeneic CRISPR-Cas9-Engineered CAR T Cells in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Phase 1 Dose Escalation Carbon Study

Cytokine Release Syndrome (CRS) Is Not Required for CAR-T Cell Efficacy in Aggressive Large B-NHL

Population Pharmacokinetic Model Identifies an Optimal Fludarabine Exposure for Improved Outcomes after CD19-Directed CAR T Cell Therapy for Aggressive B-NHL: Analysis from the Cell Therapy Consortium

Breakthrough CMV Viremia Outcomes of Letermovir Prophylaxis in Haploidentical Stem Cell Transplant with Post-Transplant Cyclophosphamide

Estimating the Lifetime Medical Cost Burden of an Allogeneic Hematopoietic Cell Transplantation Patient and the Value of Addressing the Unmet Need

Impact of CD19 CAR T-cell product type on outcomes in relapsed or refractory aggressive B-NHL

Tisagenlecleucel Vs Standard of Care As Second-Line Therapy of Primary Refractory or Relapsed Aggressive B-Cell Non-Hodgkin Lymphoma: Analysis of the Phase III Belinda Study

Bendamustine Is a Safe and Effective Regimen for Lymphodepletion before Tisagenlecleucel in Patients with Large B-Cell Lymphomas

A Multicenter Analysis of Outcomes, Toxicities, and Patterns of Use with Commercial Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed/Refractory Aggressive B-Cell Lymphomas

Safety and Efficacy of Two Anakinra Dose Regimens for Refractory CRS or Icans after CAR T-Cell Therapy

Hospitalization and Healthcare Resource Use of Omidubicel Vs Cord Blood Transplantation for Hematological Malignancies in a Global Randomized Phase III Clinical Trial

Outcomes of Aggressive B Cell Lymphoma Patients with No Evidence of Measurable Disease at the Time of CD19 Chimeric Antigen Receptor T Cell Therapy: The Experience from the CAR T Cell Consortium

Omidubicel vs standard myeloablative umbilical cord blood transplantation: results of a phase 3 randomized study

Early Infection after Allogeneic Transplant Increases NRM without Influencing Relapse Rate

Myc Expression and Tumor-Infiltrating T Cells Are Associated with Response in Patients (Pts) with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL) Treated with Tisagenlecleucel in the Juliet Trial

A Multi-Center Biologic Assignment Trial Comparing Reduced Intensity Allogeneic Hematopoietic Cell Transplantation to Hypomethylating Therapy or Best Supportive Care in Patients Aged 50-75 with Advanced Myelodysplastic Syndrome: Blood and Marrow Transplant Clinical Trials Network Study 1102

Second Autologous Stem Cell Transplant As Salvage Therapy in Multiple Myeloma - the Oregon Health and Science University Experience

A Multicenter Retrospective Analysis of Clinical Outcomes, Toxicities, and Patterns of Use in Institutions Utilizing Commercial Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed/Refractory Aggressive B-Cell Lymphomas

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only